Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00600015
First received: December 26, 2007
Last updated: August 22, 2012
Last verified: August 2012

December 26, 2007
August 22, 2012
February 2008
February 2009   (final data collection date for primary outcome measure)
  • Overall Objective Response Rate (ORR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Progression Free Survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00600015 on ClinicalTrials.gov Archive Site
  • Disease Control Rate (DCR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Duration of Response [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • 6-month PFS [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Overall Survival (OS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Progression-free survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer

This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens. Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice daily), or erlotinib (150 mg/day) and a placebo.

The rationale of this study is to combine two distinct kinase inhibitors to evaluate synergistic inhibition of angiogenesis and epidermal growth factor receptor (EGFR) signaling. Erlotinib is a oral tyrosine kinase inhibitor that targets EGFR. Sorafenib is a oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor beta, Raf-1, Flt-3, and C-kit. These agents also do not exhibit overlapping adverse event profiles which provided additional support for studying this combination therapy.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Non-Small Cell Lung Cancer
  • Drug: Erlotinib + Sorafenib
    Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
    Other Names:
    • Tarceva
    • Nexavar
  • Drug: Erlotinib + Placebo
    Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
    Other Name: Tarceva
  • Experimental: Combination Therapy
    Erlotinib + Sorafenib
    Intervention: Drug: Erlotinib + Sorafenib
  • Placebo Comparator: Placebo
    Erlotinib + Placebo
    Intervention: Drug: Erlotinib + Placebo
Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
166
February 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed locally advanced or metastatic NSCLC (unresectable stage IIIB or stage IV). Eligible histologies include adenocarcinoma and squamous cell carcinoma. Patients with recurrent disease after treatment for localized NSCLC are also eligible. Cytologic specimens obtained by brushings, washings, or needle aspiration are acceptable.
  • At least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques, or as >= 10 mm with spiral computerized tomography (CT) scan according to the Response Evaluation Criteria in Solid Tumors (RECIST).
  • Failure of at least one, and no more than two prior cytotoxic chemotherapy regimens for advanced disease (either due to progressive disease or toxicity).
  • Recovery from any toxic effects of prior therapy to <= grade 1.
  • Completion of radiation therapy at least 28 days prior to the start of study treatment (not including palliative local radiation). Previously irradiated lesions in the advanced setting cannot be included as target lesions unless clear tumor progression has been observed since the end of radiation.
  • An ECOG performance status of 0-2.
  • Absolute neutrophil count (ANC) >= 1,500, platelets >= 75,000.
  • Hemoglobin >= 9 g/dL (within 7 days prior to study treatment).
  • International normalized ratio (INR) <= 1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution
  • Serum creatinine <= 1.5 x institutional upper limit of normal (ULN) within 7 days prior to study treatment.
  • Transaminases <= 3 x institutional ULN
  • Agreement of female patients of childbearing potential and male patients who have partners of childbearing potential to use an effective form of contraception to prevent pregnancy during treatment, and for a minimum of 90 days thereafter.
  • Patients who have treated brain metastases >= 4 weeks out (with surgery and/or radiation therapy) and no evidence of CNS progression.

Exclusion Criteria:

  • Past or current history of neoplasm (other than the entry diagnosis), with the exception of treated non-melanoma skin cancer or carcinoma in-situ of the cervix, or other cancers cured by local therapy alone, and a disease-free survival (DFS) >= 3 years.
  • Patients who have mixed tumors with small-cell elements are ineligible.
  • Pregnancy or lactation.
  • Prior treatment with EGFR TKIs or VEGFR TKIs for NSCLC. [NOTE: prior cetuximab and/or bevacizumab use is permitted].
  • Significant cardiac disease within 90 days of starting study treatment
  • Myocardial infarction within 6 months prior to initiation of study treatment.
  • Cardiomegaly on chest imaging or ventricular hypertrophy on electrocardiogram (ECG)
  • Poorly controlled hypertension
  • Unstable angina (anginal symptoms at rest).
  • Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
  • Presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia.
  • A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  • A major surgical procedure, open biopsy, or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study.
  • Stroke or transient ischemic attack (TIA) within the past 6 months.
  • Any prior history of hypertensive crisis or hypertensive encephalopathy.
  • Pulmonary hemorrhage/bleeding event >= grade 2 within 28 days of study treatment.
  • Any other non-pulmonary hemorrhage/bleeding event >= grade 3 within 28 days of study treatment.
  • Evidence or history of bleeding diathesis or coagulopathy.
  • Serious non-healing wound, ulcer, or bone fracture.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00600015
SCRI LUN 160
No
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Bayer
Study Chair: David Spigel, M.D. SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP